Lukas Biomedical (ROCO:6814) EV-to-EBIT : -34.06 (As of Jun. 05, 2024)

Lukas Biomedical EV-to-EBIT Chart

Lukas Biomedical Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
EV-to-EBIT	Get a 7-Day Free Trial					-	-35.26	-	-26.25	-

Competitive Comparison of Lukas Biomedical's EV-to-EBIT

For the Biotechnology subindustry, Lukas Biomedical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lukas Biomedical's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lukas Biomedical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Lukas Biomedical's EV-to-EBIT falls into.

Lukas Biomedical EV-to-EBIT Calculation

Lukas Biomedical's EV-to-EBIT for today is calculated as:

Lukas Biomedical's current Enterprise Value is NT$1,190.3 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lukas Biomedical's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was NT$-34.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lukas Biomedical  (ROCO:6814) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Lukas Biomedical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

Lukas Biomedical's Enterprise Value for the quarter that ended in Jun. 2023 was NT$1,485.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lukas Biomedical's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was NT$-34.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lukas Biomedical EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Lukas Biomedical's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Lukas Biomedical (ROCO:6814) Business Description